Medicinal Chemistry News and Research

RSS

Potential new drug blocks pathway of deadliest cancer

Scientists at Cancer Research Technology Ltd (CRT) will present exciting new findings showing that a potent and selective inhibitor of protein kinase D called CRT0066101, inhibits the growth of pancreatic tumours.

20 Apr 2009

First compound for receptors in schizophrenia and Alzheimer's holds promise

For almost 20 years, pharmacological companies have known that certain compounds that activate two specific CNS receptors, causing them to release the neurotransmitter acetylcholine, are effective in treating the cognitive and motor problems related to both schizophrenia and Alzheimer's disease (AD).

20 Apr 2009

Antibiotics could treat cystic fibrosis, other genetic diseases

By modifying the properties of the common antibiotic gentamicin, researchers at the Technion-Israel Institute of Technology have developed what could become an effective treatment for many human genetic diseases, including cystic fibrosis (CF), Duchenne muscular dystrophy, Usher Syndrome and numerous cancers.

8 Apr 2009

BioDuro and Roche enter into strategic collaboration to provide drug discovery services

BioDuro has announced that they have entered into a strategic partnership with Roche to support discovery phase research efforts at Roche's global research sites.

6 Apr 2009

Fluorescent anesthetic compound brings new avenues for drug discovery

A collaboration of University of Pennsylvania and University of Wisconsin chemists and anesthesiologists have identified a fluorescent anesthetic compound that will assist researchers in obtaining more precise information about how anesthetics work in the body and will provide a means to more rapidly test new anesthetic compounds in the search for safer and more effective drugs.

6 Apr 2009

Platinum-based anti-tumor compounds

Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.

15 Feb 2009

Orexin - natural brain substance - blocks weight gain in mice

Mice with increased levels of a natural brain chemical don't gain weight when fed a high-fat diet, researchers at UT Southwestern Medical Center have found.

29 Jan 2009

New class of anti-inflammatory drugs

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices.

10 Dec 2008

Scientists create synthetic Heparin in more varieties

Scientists at the University of North Carolina at Chapel Hill have learned to customize a key human enzyme responsible for producing heparin, opening the door to a more effective synthetic anticoagulant as well as treatments for other conditions.

25 Nov 2008

'Intelligent' cancer drug development boosts success rates

A new era of intelligent cancer drug development has spurred a leap in the proportion of drugs reaching patients, according to a study by Cancer Research UK scientists published in Nature Reviews Drug Discovery.

17 Nov 2008

Compound found that blocks SARS virus

A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease.

12 Nov 2008

Many receptor models used in drug design may not be useful after all

It may very well be that models used for the design of new drugs have to be regarded as impractical. This is the sobering though important conclusion of the work of two Leiden University scientists published in Science this week.

5 Oct 2008

Naltrexone-derived pyridomorphinan shows promise for treatment of alcoholism

Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry.

11 Sep 2008

Galapagos acquires structure-based drug discovery from Sareum

Galapagos NV and Sareum Holdings plc has announced today that Galapagos has acquired Sareum's assets in drug discovery services, for a total cash consideration of EUR 695,000 (£553,000). These assets will position Galapagos' service division BioFocus DPI strongly in the growing field of structure-based drug discovery.

26 Aug 2008

Spice-based compound to fight against cancer

Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading.

17 Aug 2008

Diakron licenses anticoagulant drug candidate from Merck

Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

13 Aug 2008

Researchers find a cancer-inhibiting cyanobacteria that grows on coral reefs

University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.

10 Aug 2008

Discovery of new drug candidates to combat bird flu

As the specter of a worldwide outbreak of avian or "bird flu" lingers, health officials recognize that new drugs are desperately needed since some strains of the virus already have developed resistance to the current roster of anti-flu remedies.

2 Jul 2008

Discovery of mechanism of action of antibiotic able to reduce neuronal cell death in brain

Virginia Commonwealth University researchers have discovered how an antibiotic works to modulate the activity of a neurotransmitter that regulates brain functions, which eventually could lead to therapies to treat Alzheimer's disease, Huntington's disease, epilepsy, stroke, dementia and malignant gliomas.

11 May 2008

Biopharmaceutical spin-out company Domainex, secures funding

Headquartered in London, Domainex is a contract research company specialising in the provision of structural biology and chemistry services to major pharmaceutical and biotechnology firms. The Company is also developing a pipeline of pre-clinical drugs and targets.

From Domainex 23 Apr 2008